Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106880 | 0.93 | ESR1 (0.51) | ESR1ESR2EBPSIGMAR1MAPT | |
| SCHEMBL7107480 | 0.90 | ESR1 (0.46) | ESR1ESR2GRIN2CTP53MAPT | |
| SCHEMBL7110416 | 0.88 | ESR1 (0.51) | ESR1ESR2EBPSIGMAR1MAPT | |
| SCHEMBL3861641 | 0.88 | ESR1 (0.55) | ESR1ESR2EBPSIGMAR1TP53 | |
| SCHEMBL7105874 | 0.86 | ESR1 (0.44) | ESR1ESR2EBPSIGMAR1GRIN2C | |
| SCHEMBL7111025 | 0.85 | ESR1 (0.47) | ESR1ESR2EBPSIGMAR1MAPT | |
| SCHEMBL7112981 | 0.82 | ESR1 (0.47) | ESR1ESR2EBPSIGMAR1TP53 | |
| SCHEMBL7111266 | 0.81 | ESR1 (0.47) | ESR1ESR2TP53MAPTSMN1; SMN2 | |
| SCHEMBL7544137 | 0.80 | ESR1 (0.37) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL7225086 | 0.80 | ESR1 (0.37) | ESR1ESR2EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-5958916-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | ESR1 1044/4885ESR2 2130/4885EBP 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.